Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor

Eitemau Tebyg

• Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
  gan: Wakai, T, et al.
  Cyhoeddwyd: (2004)
• Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan
  gan: Yeh, Chun-Nan, et al.
  Cyhoeddwyd: (2011)
• Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours
  gan: J Dretzke, et al.
  Cyhoeddwyd: (2010-10-01)
• Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
  gan: Gauden, Ruth, et al.
  Cyhoeddwyd: (2011)
• Synchronous development of KIT positive acute myeloid leukemia in a patient with gastrointestinal stromal tumor
  gan: Joo, Young-Bin, et al.
  Cyhoeddwyd: (2010)